Brokerages Set PRA Health Sciences Inc (PRAH) Target Price at $114.25

PRA Health Sciences Inc (NASDAQ:PRAH) has received a consensus rating of “Buy” from the thirteen brokerages that are currently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $114.25.

A number of analysts have recently commented on the stock. BidaskClub lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, December 27th. Zacks Investment Research lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. ValuEngine raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research report on Monday, February 4th. SunTrust Banks boosted their price objective on shares of PRA Health Sciences to $120.00 and gave the stock an “average” rating in a research report on Monday, March 4th. Finally, Wolfe Research assumed coverage on shares of PRA Health Sciences in a research report on Tuesday. They issued a “market perform” rating on the stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Enlightenment Research LLC acquired a new position in shares of PRA Health Sciences in the fourth quarter valued at $101,000. Gideon Capital Advisors Inc. acquired a new position in shares of PRA Health Sciences in the third quarter valued at $207,000. Quantamental Technologies LLC acquired a new position in shares of PRA Health Sciences in the fourth quarter valued at $221,000. Logan Capital Management Inc. acquired a new position in shares of PRA Health Sciences in the third quarter valued at $236,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of PRA Health Sciences in the third quarter valued at $236,000. 98.14% of the stock is currently owned by hedge funds and other institutional investors.

Shares of PRAH stock traded down $1.12 during trading on Thursday, reaching $109.85. The company’s stock had a trading volume of 126,741 shares, compared to its average volume of 574,727. The company has a quick ratio of 0.87, a current ratio of 0.87 and a debt-to-equity ratio of 1.03. The firm has a market cap of $7.19 billion, a PE ratio of 27.95, a P/E/G ratio of 1.59 and a beta of 1.12. PRA Health Sciences has a one year low of $79.20 and a one year high of $121.98.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Article: Asset Allocation Models, Which is Right For You?

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.